An update in guillain-barré syndrome

Area of Science:

• Neurology
• Immunology
• Clinical Neuroscience

Background:

• Guillain-Barré syndrome (GBS), first described in 1916, has evolved from a solely demyelinating pathology to include axonal subtypes.
• GBS is now understood as an immunological response to antecedent events, primarily infections.
• The syndrome encompasses diverse subtypes with varying immunological mechanisms, some of which require further elucidation.

Purpose of the Study:

• To review the expanded knowledge of Guillain-Barré syndrome (GBS) over its near 100-year history.
• To highlight current understanding of GBS pathophysiology, including immunological mechanisms and identified subtypes.
• To discuss ongoing research into prognostic factors, therapeutic influences like intravenous immunoglobulin (IvIg) pharmacokinetics, and novel treatment strategies.

Main Methods:

• Literature review of historical and contemporary research on Guillain-Barré syndrome.
• Analysis of evolving understanding of GBS pathology, including demyelinating and axonal subtypes.
• Examination of research databases focusing on prognostic factors and therapeutic interventions.

Main Results:

• Recognition of both demyelinating and axonal subtypes of GBS.
• Identification of infections as common triggers and GBS as an immunological response.
• Increasing evidence implicates complement-fixing antibodies against gangliosides and novel antibodies against neurofascin in nerve damage.

Conclusions:

• GBS is a complex clinical syndrome of acute inflammatory neuropathy with distinct immunological mechanisms.
• Complement-fixing antibodies against peripheral nerve gangliosides are significant contributors to nerve damage.
• Future research directions include complement inhibition as a potential therapeutic strategy for GBS.